Akari Therapeutics, Plc Capital Expenditures
Akari Therapeutics, Plc (AKTX) reported Capital Expenditures of $0 for the 12-month period ending 2023-12-31, per its 8-K filed 2024-09-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2024-09-06
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for the quarter ending 2016-06-30 was $5.90K.
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for the quarter ending 2016-03-31 was $42.08K.
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for the quarter ending 2015-06-30 was $0.00.
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for the quarter ending 2015-03-31 was $0.00.
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for fiscal 2013 was $0.00.
- Akari Therapeutics, Plc payments to acquire property, plant, and equipment for fiscal 2012 was $0.00.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed | Payments to Acquire Property, Plant, and Equipment 99 month | Payments to Acquire Property, Plant, and Equipment 111 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 8-K · filed 2024-09-06 | |||||
| 2022-12-31 | $142.25K 8-K · filed 2024-09-06 | |||||
| 2019-12-31 | $0.00 20-F · filed 2020-03-31 | |||||
| 2018-12-31 | $0.00 20-F · filed 2020-03-31 | |||||
| 2018-06-30 | $0.00 6-K · filed 2018-09-27 | |||||
| 2017-12-31 | $36.88K 20-F · filed 2020-03-31 | |||||
| 2017-06-30 | $36.88K 6-K · filed 2018-09-27 | |||||
| 2016-12-31 | $54.75K 20-F · filed 2019-04-23 | |||||
| 2016-06-30 | $5.90K derived: 6-K 6 month − 10-Q 3 month · filed 2017-08-10 | $47.98K 6-K · filed 2017-08-10 | ||||
| 2016-03-31 | $42.08K 10-Q · filed 2016-05-12 | |||||
| 2015-12-31 | $10.56K 20-F · filed 2018-07-18 | |||||
| 2015-06-30 | $0.00 derived: 6-K 6 month − 10-Q 3 month · filed 2017-04-14 | $0.00 6-K · filed 2017-04-14 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-12 | |||||
| 2014-12-31 | $0.00 20-F · filed 2017-03-31 | $57.00K 10-K · filed 2015-02-11 | ||||
| 2013-12-31 | $0.00 10-K · filed 2015-02-11 | $10.00K 20-F · filed 2014-03-24 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-11 | $9.00K 20-F/A · filed 2013-04-19 | ||||
| 2011-12-31 | $0.00 20-F · filed 2014-03-24 | |||||
| 2010-12-31 | $0.00 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |